More so than any other core function of the biopharma industry, clinical trials have been buffeted by the prevailing winds of the pandemic.
From the turbulent waves of infection causing overstretched healthcare facilities, inaccessible sites and patient availability through to the relative plain sailing of mammoth Phase III vaccine trials, COVID-19 has permanently changed the nature of clinical research.
This session explores the negative and positive aspects that the clinical trial ecosystem has either endured or capitalized upon, and attempts to answer the question as to whether we have emerged from the storm in a stronger position than before.
The presentation will touch upon topics such as:
- disruption to ongoing and planned trials
- patient engagement in clinical research
- digital and technology acceleration
- sponsor strategies and dynamics
Date: Wednesday, June 15th 2022
Time: 9:00 – 11:00
Venue: Medicon Valley Alliance, Arne Jacobsens Allé 15, 2300 Copenhagen S, Denmark – Meeting room: Auditorium
Program
| 9:00 | Networking, registration and light breakfast |
| 9:30 | Welcome David Munis Zepernick, Head of Member Engagement and Communication, Medicon Valley Alliance |
| 9:35 | Pharma Intelligence Introduction Alex Harris, Northern Europe & Israel Commercial Lead, Pharma Intelligence |
| 9:40 | Measuring the COVID-19 effect on clinical trials Daniel Chancellor, Thought Leadership and Consulting Director, Informa Pharma Intelligence |
| 10:10 | Q&A |
| 10:30 | Networking |
| 11:00 | End of Good Morning Meeting |
Speakers
 |
Daniel Chancellor, Thought Leadership and Consulting Director, Informa Pharma Intelligence
Daniel has over a decade of experience as an analyst in the biopharma industry, spanning roles in drug discovery, market analysis, competitive intelligence, and strategic consulting. He now develops and leads Informa Pharma Intelligence’s Thought Leadership program, producing materials that help clients across a range of hot topics in the biopharma industry. As part of this, Daniel regularly participates in webinars, conferences, and other speaking arrangements, and he has provided expert insights across a wide range of leading industry and business publications. Prior to joining Informa, Daniel worked as a medicinal chemist at the UK biotech company Summit Therapeutics and graduated with First Class Honours in Natural Sciences from the University of Bath.
|
|
In collaboration with | |
 |
 |